Stereotactic Radiosurgery and Anti-PD-1+CTLA-4 Therapy, Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases

被引：0
|
作者：
Dohm, A. E. [1 ]
Kalagotla, H. [2 ]
Jiang, S. X. [2 ]
Bhandari, M. [3 ]
Mills, M. N. [1 ]
Graham, J. [1 ]
Khushalani, N. I. [2 ]
Forsyth, P. [4 ]
Etame, A. B. [4 ]
Liu, J. K. [4 ]
Tran, N. [4 ]
Vogelbaum, M. [5 ]
Yu, H. H. M. [5 ]
Oliver, D. E. [1 ]
Ahmed, K. A. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Geetanjali Canc Ctr, Udaipur, Rajasthan, India
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2181
引用
收藏
页码：E82 / E82
页数：1
相关论文
共 50 条
  • [1] Stereotactic radiosurgery and anti-PD-1+CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases
    Dohm, Ammoren E.
    Nakashima, Justyn Y.
    Kalagotla, Hruday
    Jiang, Shirley X.
    Tang, Joseph D.
    Bhandari, Menal
    Kim, Youngchul
    Graham, Jasmine A.
    Khushalani, Nikhil I.
    Forsyth, Peter A.
    Etame, Arnold B.
    Liu, James K.
    Tran, Nam D.
    Vogelbaum, Michael A.
    Wuthrick, Evan J.
    Yu, Hsiang-Hsuan Michael
    Oliver, Daniel E.
    Ahmed, Kamran A.
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [2] Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
    Ahmed, K. A.
    Abuodeh, Y. A.
    Echevarria, M. I.
    Arrington, J. A.
    Stallworth, D. G.
    Hogue, C.
    Naghavi, A. O.
    Kim, S.
    Kim, Y.
    Patel, B. G.
    Sarangkasiri, S.
    Johnstone, P. A. S.
    Sahebjam, S.
    Khushalani, N. I.
    Forsyth, P. A.
    Harrison, L. B.
    Yu, M.
    Etame, A. B.
    Caudell, J. J.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2288 - 2294
  • [3] Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF Inhibitor, or Conventional Chemotherapy
    Ahmed, K. A.
    Abuodeh, Y. A.
    Hogue, C.
    Stallworth, D. G.
    Naghavi, A. O.
    Kim, S.
    Sarangkasiri, S.
    Johnstone, P. A. S.
    Yu, H. M.
    Khushalani, N. I.
    Etame, A. B.
    Harrison, L. B.
    Caudell, J. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S58 - S59
  • [4] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [5] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [6] CLINICAL OUTCOMES IN THE MANAGEMENT OF MELANOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY AND ANTI-PD-1+CTLA-4
    Tang, Joseph
    Dohm, Ammoren
    Kalagotla, Hruday
    Bhandari, Menal
    Kim, Youngchul
    Graham, Jasmine
    Khushalani, Nikhil
    Forsyth, Peter
    Etame, Arnold
    Liu, James
    Tran, Nam
    Vogelbaum, Michael
    Yu, Michael
    Ahmed, Kamran
    Oliver, Daniel
    NEURO-ONCOLOGY, 2022, 24 : 51 - 51
  • [7] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [8] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
    Gide, Tuba N.
    Quek, Camelia
    Menzies, Alexander M.
    Tasker, Annie T.
    Shang, Ping
    Holst, Jeff
    Madore, Jason
    Lim, Su Yin
    Velickovic, Rebecca
    Wongchenko, Matthew
    Yan, Yibing
    Lo, Serigne
    Carlino, Matteo S.
    Guminski, Alexander
    Saw, Robyn P. M.
    Pang, Angel
    McGuire, Helen M.
    Palendira, Umaimainthan
    Thompson, John F.
    Rizos, Helen
    da Silva, Ines Pires
    Batten, Marcel
    Scolyer, Richard A.
    Long, Georgina V.
    Wilmott, James S.
    CANCER CELL, 2019, 35 (02) : 238 - +
  • [10] Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
    Campbell, Katie M.
    Amouzgar, Meelad
    Pfeiffer, Shannon M.
    Howes, Timothy R.
    Medina, Egmidio
    Travers, Michael
    Steiner, Gabriela
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Larkin, James
    Hodi, F. Stephen
    Boffo, Silvia
    Salvador, Lisa
    Tenney, Daniel
    Tang, Tracy
    Thompson, Marshall A.
    Spencer, Christine N.
    Wells, Daniel K.
    Ribas, Antoni
    CANCER CELL, 2023, 41 (04) : 791 - +
12345